Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 21.6% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 55,426 shares of the biopharmaceutical company’s stock after purchasing an additional 9,845 shares during the period. Mirae Asset Global Investments Co. Ltd.’s holdings in Regeneron Pharmaceuticals were worth $38,305,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of the stock. Paragon Capital Management Inc. acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter worth approximately $1,257,000. 1858 Wealth Management LLC acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter worth approximately $224,000. Avitas Wealth Management LLC boosted its stake in Regeneron Pharmaceuticals by 12.7% in the 4th quarter. Avitas Wealth Management LLC now owns 372 shares of the biopharmaceutical company’s stock worth $265,000 after purchasing an additional 42 shares in the last quarter. Redwood Wealth Management Group LLC boosted its stake in Regeneron Pharmaceuticals by 4.2% in the 4th quarter. Redwood Wealth Management Group LLC now owns 497 shares of the biopharmaceutical company’s stock worth $354,000 after purchasing an additional 20 shares in the last quarter. Finally, Ninety One UK Ltd boosted its stake in Regeneron Pharmaceuticals by 14.4% in the 4th quarter. Ninety One UK Ltd now owns 78,005 shares of the biopharmaceutical company’s stock worth $55,565,000 after purchasing an additional 9,820 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Trading Up 4.5 %

Shares of REGN opened at $697.05 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 52-week low of $642.00 and a 52-week high of $1,211.20. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The firm’s fifty day moving average is $719.16 and its two-hundred day moving average is $918.90. The stock has a market cap of $76.60 billion, a PE ratio of 17.25, a price-to-earnings-growth ratio of 1.60 and a beta of 0.08.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 33.61% and a return on equity of 16.88%. The company had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter in the previous year, the company posted $11.86 EPS. The firm’s quarterly revenue was up 10.3% on a year-over-year basis. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.75 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.50%.

Analyst Ratings Changes

A number of analysts recently commented on the stock. Wolfe Research assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 target price for the company. Sanford C. Bernstein reduced their price target on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a research report on Tuesday, January 7th. StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. Cantor Fitzgerald reissued a “neutral” rating and set a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 23rd. Finally, Canaccord Genuity Group lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 17th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $982.43.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.